Watch TNYA. Know when insiders buy.
One email the day a filing lands. Free.
TNYA
Tenaya Therapeutics, Inc.
0.57
−0.04 −6.29%
USD · close Oct 1
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
54
WATCH · shorts 54
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $126.9MP/E —DIV YIELD —FCF YIELD -41.44%REV TTM —NET INCOME −$103.1MNET CASH —52W 0.55 – 2.10SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $1.1M | — | — | −$44.1M | −$43.4M | — | -0.20 | −$3.6M | $159K | −$3.7M | Aug 5 |
| Q1 2026 · Mar 31 | $225K | — | — | −$20.1M | −$19.3M | — | -0.09 | −$19.2M | $11K | −$19.2M | Aug 5 |
| Q4 2025 · Dec 31derived | — | — | — | −$20.8M | −$20.2M | — | -0.11 | −$13.9M | $67K | −$14M | Mar 11 |
| Q3 2025 · Sep 30 | — | — | — | −$20.9M | −$20.3M | — | -0.12 | −$15.6M | $26K | −$15.6M | Nov 10 |
| Q2 2025 · Jun 30 | $0 | — | — | −$24.1M | −$23.3M | — | -0.14 | −$15.6M | $142K | −$15.8M | Aug 5 |
| Q1 2025 · Mar 31 | $0 | — | — | −$27.5M | −$26.9M | — | -0.24 | −$23.1M | $383K | −$23.5M | Aug 5 |
| Q4 2024 · Dec 31derived | — | — | — | −$24.7M | −$23.8M | — | -0.27 | −$18.4M | $204K | −$18.6M | Mar 11 |
| Q3 2024 · Sep 30 | — | — | — | −$26.7M | −$25.6M | — | -0.30 | −$19.8M | $184K | −$20M | Nov 10 |
| Q2 2024 · Jun 30 | — | — | — | −$30.8M | −$29.4M | — | -0.34 | −$23.6M | $73K | −$23.7M | Nov 10 |
| Q1 2024 · Mar 31 | — | — | — | −$33.8M | −$32.2M | — | -0.40 | −$28.7M | $564K | −$29.2M | Nov 10 |
| Q4 2023 · Dec 31derived | — | — | — | −$31.4M | −$29.9M | — | -0.40 | −$21.9M | $394K | −$22.3M | Mar 10 |
| Q3 2023 · Sep 30 | — | — | — | −$30.9M | −$29.1M | — | -0.39 | −$23.6M | $8K | −$23.6M | Nov 6 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$93.3M | −$90.6M | — | -0.59 | −$68.3M | $618K | −$68.9M | — | — |
| FY2024 · to Dec 31 | — | — | −$115.9M | −$111.1M | — | -1.31 | −$90.5M | $1M | −$91.5M | — | — |
| FY2023 · to Dec 31 | — | — | −$131.2M | −$124.1M | — | -1.68 | −$102.1M | $1.2M | −$103.3M | — | — |
| FY2022 · to Dec 31 | — | — | −$125.6M | −$123.7M | — | -2.76 | −$104.4M | $20.6M | −$125.1M | — | — |
| FY2021 · to Dec 31 | — | — | −$72.8M | −$72.7M | — | -4.10 | −$60.8M | $25.1M | −$85.9M | $13K | — |
| FY2020 · to Dec 31 | — | — | −$38.9M | −$38.4M | — | -39.50 | −$35.4M | $9.8M | −$45.2M | $1K | — |
Every number comes from Tenaya Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.